是什么让一家公司选择暂停一款前景积极的资产的2期临床,尤其是在所有的关键临床准备完成之后?——没钱。日前,微生物组疗法领域的先驱企业Seres Therapeutics发布了项目和企业更新,为了节约资金延长公司运营时间,将暂停其核心项目SER-155的进一步开发,并削减30%的员工。根据该公司公告,此举将现金流延长至2026年第三季度。同时,Seres将积极寻找新的资金支持。核心管线前景积极SER...
Source Link是什么让一家公司选择暂停一款前景积极的资产的2期临床,尤其是在所有的关键临床准备完成之后?——没钱。日前,微生物组疗法领域的先驱企业Seres Therapeutics发布了项目和企业更新,为了节约资金延长公司运营时间,将暂停其核心项目SER-155的进一步开发,并削减30%的员工。根据该公司公告,此举将现金流延长至2026年第三季度。同时,Seres将积极寻找新的资金支持。核心管线前景积极SER...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.